Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL compounds are designed to precisely target specific proteins that reduce the body’s ability to fight cancer without the need for specialized formulations or drug delivery systems, and are designed to make immune cells effective in killing tumor cells. Its lead product candidate, PH-762, is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.